The ethical significance of antimicrobial resistance

Public Health Ethics

Volumn 8, Issue 3, 2015, Pages 209-224

  Littmann, Jasper ^a   Viens, A M ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGRICULTURAL PROCEDURES; ANTIBIOTIC RESISTANCE; ARTICLE; BEHAVIOR CHANGE; DIAGNOSTIC TEST; DRUG DEVELOPMENT; ENVIRONMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; JUSTICE; LAW; MEDICAL ETHICS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESOURCE ALLOCATION; RISK;

EID: 84975687576     PISSN: 17549973     EISSN: 17549981     Source Type: Journal    
DOI: 10.1093/phe/phv025     Document Type: Article

References (106)

1. Aiello, A. E., King, N. B. and Foxman, B. (2006). Ethical Conflicts in Public Health Research and Practice Antimicrobial Resistance and the Ethics of Drug Development. American Journal of Public Health, 96, 1910-1914.
2. Aiello, A. E. and Larson, E. E. (2002). What is the Evidence for a Causal Link between Hygiene and Infections? The Lancet Infectious Diseases, 2, 103-110.
3. Anomaly, J. (2009). Harm to others: The Social Cost of Antibiotics in Agriculture. Journal of Agricultural and Environmental Ethics, 22, 423-435.
4. Anomaly, J. (2010). Combating Resistance: The Case for a Global Antibiotics Treaty. Public Health Ethics, 3, 13-22.
5. Anomaly, J. (2013). Collective Action and Individual Choice: Rethinking How We Regulate Narcotics and Antibiotics. Journal of Medical Ethics, 39, 752-756.
6. Anomaly, J. (2015). What's Wrong With Factory Farming. Public Health Ethics, 8, 246-254.
7. Baker, S. (2015). A Return to the Pre-Antimicrobial Era? Science, 347, 1064-1066.
8. Battin, M. P., Francis, L. P., Jacobson, J. A. and Smith, C. B. (2009). The Patient As Victim and Vector: Ethics and Infectious Disease. New York: Oxford University Press.
9. Bengtson, B. and Greko, C. (2014). Antibiotic Resistance - Consequences for Animal Health, Welfare, and Food Production. Uppsala Journal of Medical Sciences, 119, 96-102.
10. Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A. and Gilbert, D. (2013). 10×'20 Progress - Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America. Clinical Infectious Diseases, 56, 1685-1694.
11. Brown, K., Kulis, J., Thomson, B., Chapman, T. and Mawhinney, D. (2006). Occurrence of Antibiotics in Hospital, Residential, and Dairy Effluent, Municipal Wastewater, and the Rio Grande in New Mexico. Science of the Total Environment, 366, 772-783.
12. Brownsword, R. (2009). Rights, Responsibility and Stewardship: Beyond Consent. In Widdows, H. and Mullen, C. (eds), The Governance of Genetic Information: Who Decides? Cambridge: Cambridge University Press, pp. 99-125.
13. Cars, O., Högberg, L. D., Murray, M., Nordberg, O., Sivaraman, S., Lundborg, C. S., So, A. D. and Tomson, G. (2008). Meeting the Challenge of Antibiotic resistance. British Medical Journal, 337, a1438.
14. Cars, O. and Nathan, C. (2014). Antibiotic Resistance - Problems, Progress, and Prospects. New England Journal of Medicine, 371, 1761-1763.
15. Casewell, M., Friis, C., Marco, E., McMullin, P. and Phillips, I. (2003). The European ban on Growth-Promoting Antibiotics and Emerging Consequences for Human and Animal Health. Journal of Antimicrobial Chemotherapy, 52, 159-161.
16. Centers for Disease Control and Prevention. (2013). Antibiotic Resistance Threats in the United States 2013. Washington: CDC.
17. Centers for Disease Control and Prevention. (2014). Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: CDC.
18. Coast, J. and Smith, R. D. (2015). Distributional Considerations in Economic Responses to Antimicrobial Resistance. Public Health Ethics, 8, 225-237.
19. Coggon, J. (2011). What Help is a Steward? Stewardship, Political Theory, and Public Health Law and Ethics. Northern Ireland Legal Quarterly, 62, 599-616.
20. Coleman, C. J. E., Reis, A. and Selgelid, M. (2010). Guidance on Ethics of Tuberculosis Prevention, Care and Control. Geneva: World Health Organization.
21. Collignon, P., Athukorala, P.-C., Senanayake, S. and F, K. (2015). Antimicrobial Resistance: The Major Contribution of Poor Governance and Corruption to this Growing Problem. PLoS One, 10, e0116746.
22. Davies, S. C. and Gibbens, N. (2013). UK Five Year Antimicrobial Resistance Strategy 2013-2018. London: Department of Health.
23. Davies, S. C., Grant, J. and Catchpole, M. (2013). The Drugs Don't Work: A Global Threat. Penguin Specials. London: Penguin.
24. Dawson, A. and Jennings, B. (2012). The Place of Solidarity in Public Health Ethics. Public Health Review, 34, 65-79.
25. Dawson, A. and Verweij, M. (2008). The Steward of the Millian State. Public Health Ethics, 1, 193-195.
26. Dawson, A. and Verweij, M. (2012). Solidarity: A Moral Concept in Need of Clarification. Public Health Ethics, 5, 1-5.
27. Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., Brennan, P. J., Billeter, M. and Hooton, T. M. (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 44, 159-177.
28. Drive, A. B. (2014). Driving Reinvestment in R&D for Antibiotics and Advocating their Responsible use, available from: http://drive-ab.eu [accessed 17 December 2014].
29. Enemark, C. (2013). Drug-Resistant Tuberculosis: Security, Ethics and Global Health. Global Society, 27, 159-177.
30. European Commission. (2010). Special Eurobarometer: Antimicrobial Resistance. Brussels: European Commission.
31. European Medicines Agency. (2014). Sales of Veterinary Antimicrobial Agents in 256 EU/EEA Countries in 2012. In European Surveillance of Veterinary Antimicrobial Consumption. London: EMA.
32. Fidler, D. P. (1998). Legal Issues Associated with Antimicrobial Drug Resistance. Emerging Infectious Diseases, 4, 169-177.
33. Fidler, D. P., Gostin, L. O. and Markel, H. (2007). Through the Quarantine Looking Glass: Drug-Resistant Tuberculosis and Public Health Governance, Law, and Ethics. The Journal of Law, Medicine & Ethics, 35, 616-628.
34. Food and Drug Administration (2010). The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals. Rockville, MD: U.S. Department of Health and Human Services.
35. Fox, C. (2011). Resisting Antibiotic Resistance: Legal Strategies to Maintain Man's Dominion Over Microbes. Houston Journal of Health Law and Policy, 12, 35-62.
36. Frenk, J., Gómez-Dantés, O. and Moon, S. (2014). From Sovereignty to Solidarity: A Renewed Concept of Global Health for an Era of Complex Interdependence. The Lancet, 383, 94-97.
37. Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P. and Bayona, J. (2010). Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Threat to Global Control of Tuberculosis. The Lancet, 375, 1830-1843.
38. Garau, J. (2006). Impact of Antibiotic Restrictions: The Ethical Perspective. Clinical Microbiology and Infection, 12, 16-24.
39. Gerber, J. S., Prasad, P. A., Fiks, A. G., Localio, A. R., Grundmeier, R. W., Bell, L. M., Wasserman, R. C., Keren, R. and Zaoutis, T. E. (2013). Effect of an Outpatient Antimicrobial Stewardship Intervention on Broad-Spectrum Antibiotic Prescribing by Primary Care Pediatricians: A Randomized Trial. Journal of the American Medical Association, 309, 2345-2352.
40. Goldman, M. (2012). The Innovative Medicines Initiative: A European Response to the Innovation Challenge. Clinical Pharmacology & Therapeutics, 91, 418-425.
41. Gosseries, A. and Meyer, L. (eds) (2009) Intergenerational Justice. Oxford: Oxford University Press.
42. Gostin, L. O. (2014). Global Health Law. Cambridge, MA: Harvard University Press.
43. Hardin, G. (1968). The Tragedy of the Commons. Science, 162, 1243-1248.
44. Harris, J. and Holm, S. (1995). Is there a Moral Obligation not to Infect Others? British Medical Journal, 311, 1215-1217.
45. Health Protection Agency. (2004). Overview of Antimicrobial Usage and Bacterial Resistance in Selected Human and Animal Pathogens in the UK: 2004. A Joint Report. Communicable Disease Surveillance Center Northern Ireland, Food Standards Agency, London, Health Protection Agency, Veterinary Laboratories Agency.
46. Heyman, G., Cars, O., Bejarano, M.-T. and Peterson, S. (2014). Access, Excess, and Ethics - Towards a Sustainable Distribution Model for Antibiotics. Upsala Journal of Medical Sciences, 119, 134-141.
47. Hoffman, S. J., Outterson, K., Røttingen, J.-A., Cars, O., Clift, C., Rizvi, Z., Rotberg, F., Tomsonh, G. R. and Zorzetd, A. (2015). An International Legal Framework to Address Antimicrobial Resistance. Bulletin of the World Health Organization, 93, 66.
48. Horowitz, J. B. and Moehring, H. B. (2004). How Property Rights and Patents Affect Antibiotic Resistance. Health Economics, 13, 575-583.
49. Jennings, B. (2015). Relational Liberty Revisited: Membership, Solidarity and a Public Health Ethics of Place. Public Health Ethics, 8, 7-17.
50. Jochelson, K. (2005). Nanny or Steward? The Role of Government in Public Health. London: King's Fund.
51. Kesselheim, A. and Outterson, K. (2010). Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals. Health Affairs, 29, 1689-1696.
52. Kollef, M. H. and Micek, S. T. (2014). Rational use of Antibiotics in the ICU: Balancing Stewardship and Clinical Outcomes. Journal of the American Medical Association 312, 1403-1404.
53. Krishnamurthy, M. (2013). Political Solidarity, Justice, and Public Health. Public Health Ethics, 6, 129-141.
54. Larsson, D. (2014). Pollution from Drug Manufacturing: Review and Perspectives. Philosphical Transactions of the Royal Society B, 369, 20130571.
55. Laximinarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., Greko, C., So, A. D., Bigdeli, M., Tomson, G., Woodhouse, W., Ombaka, E., Peralta, A. Q., Qamar, F. N., Mir, F., Kariuki, S., Bhutta, Z. A., Coates, A., Bergstrom, R., Wright, G. D., Brown, E. D. and Cars, O. (2013). Antibiotic Resistance - the Need for Global Solutions. The Lancet Infectious Diseases, 13, 1057-1098.
56. Laxminarayan, R. and Malani, A. (2007). Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance. Washington: Resources for the Future Institute.
57. Lecky, D. M. and McNulty, C. A. M. (2013). Current Initiatives to Improve Prudent Antibiotic use Amongst School-aged Children. Journal of Antimicrobial Chemotherapy, 68, 2428-2430.
58. Leibovici, L., Paul, M. and Ezra, O. (2012). Ethical Dilemmas in Antibiotic Treatment. Journal of Antimicrobial Chemotherapy, 67, 12-16.
59. Levy, S. B. (2002). The Antibiotic Paradox. Cambridge, MA: Perseus Publishing.
60. Littmann, J., Buyx, A. and Cars, O. (2015). Antibiotic Resistance: An Ethical Challenge. International Journal of Antimicrobial Agents, http://dx.doi. org/10.1016/j.ijantimicag.2015.06.010.
61. Littmann, J. (2014). Antimicrobial Resistance and Distributive Justice. London: University College (PhD dissertation).
62. Macklin, R. (1981). Can Future Generations Correctly Be Said to Have Rights? In Partridge, E. (ed.), Responsibilities to Future Generations. New York, NY: Prometheus Books, pp. 157-166.
63. Maralles, M. A. (2010). Strengthening Health Systems to Improve Access to Antimicrobials and the Containment of Resistance. In Sosa, A. J., Byarugaba, D. K., Amabile-Cuevas, C. F., Hsueh, P.-R., Kariuki, S. and Okeke, I. N. (eds), Antimicrobial Resistance in Developing Countries. New York: Springer.
64. McCullough, A. R., Rathbone, J., Parekh, S., Hoffmann, T. C. and Del Mar, C. B. (2015). Not in my Backyard: a Systematic Review of Clinicians' Knowledge and Beliefs About Antibiotic Resistance. Journal of Antimicrobial Chemotherapy, http://jac.oxfordjournals. org/content/early/2015/06/19/jac.dkv164.full.
65. McNulty, C. A. M., Lecky, D. M., Farrell, D., Kostkova, P., Adriaenssens, N., Koprivová Herotová, T., Holt, J., Touboul, P., Merakou, K., Koncan, R., Olczak-Pienkowska, A., Brito Avô , A. and Campos, J. (2011). Overview of e-Bug: An Antibiotic and Hygiene Educational Resource for Schools. Journal of Antimicrobial Chemotherapy 66(Suppl 5), v3-v12.
66. Metley, J. P., Shea, J. A., Crossette, L. B. and Asch, D. A. (2002). Tensions in Antibiotic Prescribing: Pitting Societal Concerns Against the Interests of Individual Patients. Journal of General Internal Medicine, 17, 87-94.
67. Millar, M. (2011). Can Antibiotic use be Both Just And Sustainable⋯ or Only More or Less So? Journal of Medical Ethics, 37, 153-157.
68. Millar, M. (2012). Constraining the use of Antibiotics: Applying Scanlon's Contractualism. Journal of Medical Ethics, 38, 465-469.
69. Millar, M. R. (2015). The Choice to Travel: Health Tourists and the Spread of Antibiotic Resistance. Public Health Ethics, 8, 238-245.
70. Morel, C. and Mossialos, E. (2010). Stoking the Antibiotic Pipeline. British Medical Journal, 340, c2115.
71. Mulgan, T. (2006). Future People. A Moderate Consequentialist Account of our Obligations to Future Generations. Oxford: Clarendon Press.
72. Nuffield Council on Bioethics. (2007). Public Health: Ethical Issues. London: Nuffield Council on Bioethics.
73. O'Neill, J. (2014). Review on Antimicrobial Resistance: Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. London: Wellcome Trust.
74. Okeke, I. N. (2010). Poverty and Root Causes of Resistance in Developing Countries. In Sosa, A. d. J., Byarugaba, D. K., Amabile-Cuevas, C. F., Hsueh, P.-R., Kariuki, S., and Okeke, I. N. (eds), Antimicrobial Resistance in Developing Countries. New York: Springer, pp. 27-36.
75. Outterson, K., Pogge, T. and Hollis, A. (2011). Combating Antibiotic Resistance Through The Health Impact Fund. In Boston University School of Law Working Paper No. 11-30. Boston: Boston University School of Law.
76. Outterson, K., Powers, J. H., Daniel,G. W.andMcClellan, M. B. (2015). Repairing the Broken Market for Antibiotic Innovation. Health Affairs, 34, 277-285.
77. Partridge, E. (1990). On the Rights of Future People. In Scherer, D. (ed.), Upstream/Downstream: Issues in Environmental Ethics. Philadelphia: Temple University. pp. 40-66.
78. Pogge, T. (ed.) (2007). Freedom from Poverty as a Human Right Who Owes What to the Very Poor? Oxford: Oxford University Press.
79. Powers, M. and Faden, R. (2008). Social Justice: The Moral Foundations of Public Health and Health Policy. Oxford: Oxford University Press.
80. Prainsack, B. and Buyx, A. (2011). Solidarity: Reflections on an Emerging Concept in Bioethics. London: Nuffield Council on Bioethics.
81. Rawls, J. (1999). The Law of Peoples. Cambridge, MA: Harvard University Press.
82. Rex, J. H. (2014). ND4BB: Addressing the Antimicrobial Resistance Crisis. Nature Reviews Microbiology, 12, 231-232.
83. Rincon, P. (2014). Antibiotics to be Focus of 10m Longitude Prize. London: BBC News, available from http://www.bbc.com/news/science-environment-28027376 [accessed 26 June 2015].
84. Risse, M. (2005). What We Owe to the Global Poor. The Journal of Ethics, 9, 81-117.
85. Rollin, B. (2001). Ethics, Science, and Antimicrobial Resistance. Journal of Agricultural and Environmental Ethics, 14, 29-37.
86. Sage, W. M. and Hyman, D. A. (2010). Combating Antimicrobial Resistance: Regulatory Strategies and Institutional Capacity. Tulane Law Review, 84, 781-839.
87. Saltman, R. B. and Ferroussier-Davis, O. (2000). The Concept of Stewardship in Health Policy. Bulletin of the World Health Organization, 78, 732-739.
88. Selgelid, M. J. (2007). Ethics and Drug Resistance. Bioethics, 21, 218-229.
89. Simpson, S. A., Wood, F. and Butler, C. C. (2007). General Practitioners' Perceptions of Antimicrobial Resistance: A Qualitative Study. Journal of Antimicrobial Chemotherapy, 59, 292-296.
90. Singh, J., Bhan, A. and Upshur, R. (2013). Diagnosis of Drug-Resistant TB and Provision of Second-Line TB Treatment in India: Some Ethical Considerations. Indian Journal of Medical Ethics, 10, 110-114.
91. Smith, R. and Coast, J. (2013). The True Cost of Antimicrobial Resistance. British Medical Journal, 346, f1493.
92. So, A. D., Ruiz-Esparza, Q., Gupta, N. and Cars, O. (2012). 3Rs for Innovating Novel Antibiotics: Sharing Resources, Risks, and Rewards. British Medical Journal, 344, e1782.
93. Spellberg, B., Bartlett, J. G. and Gilbert, D. N. (2013). The Future of Antibiotics and Resistance. New England Journal of Medicine, 368, 299-302.
94. Tyler, T. R. (2006). Why People Obey the Law. Princeton, NJ: Princeton University Press.
95. Venkatapuram, S. (2013). Health Justice: An Argument from the Capabilities. London: Polity Press.
96. Verweij, M. (2005). Obligatory Precautions against Infection. Bioethics, 19, 323-335.
97. Viens, A. M. and Littmann, J. (2015). Is Antibiotic Resistance a Slowly Emerging Disaster? Public Health Ethics, 8, 255-265.
98. Wenzel, R. (2004). The Antibiotic Pipeline-Challenges, Costs, and Values. New England Journal of Medicine, 351, 523-526.
99. Wong, V. K., Baker, S., Pickard, D. J., Parkhill, J., Page, A. J., Feasey, N. A., Kingsley, R. A., Thomson, N. R., Keane, J. A., Weill, F.-X., Edwards, D. J., Hawkey, J., Harris, S. R., Mather, A. E., Cain, A. K., Hadfield, J., Hart, P. J., Thieu, N. T. V., Klemm, E. J., Glinos, D. A., Breiman, R. F., Watson, C. H., Kariuki, S., Gordon, M. A., Heyderman, R. S., Okoro, C., Jacobs, J., Lunguya, O., Edmunds, W. J., Msefula, C., Chabalgoity, J. A., Kama, M., Jenkins, K., Dutta, S., Marks, F., Campos, J., Thompson, C., Obaro, S., MacLennan, C. A., Dolecek, C., Keddy, K. H., Smith, A. M., Parry, C. M., Karkey, A., Mulholland, E. K., Campbell, J. I., Dongol, S., Basnyat, B., Dufour, M., Bandaranayake, D., Naseri, T. T., Singh, S. P., Hatta, M., Newton, P., Onsare, R. S., Isaia, L., Dance, D., Davong, V., Thwaites, G., Wijedoru, L., Crump, J. A., De Pinna, E., Nair, S., Nilles, E. J., Thanh, D. P., Turner, P., Soeng, S., Valcanis, M., Powling, J., Dimovski, K., Hogg, G., Farrar, J., Holt, K. E. and Dougan, G. (2015). Phylogeographical Analysis of the Dominant Multidrug-resistant H58 Clade of Salmonella Typhi Identifies Inter-and Intracontinental Transmission Events. Nature Genetics, 47, 632-639.
100. World Economic Forum. (2013). Global Risks 2013-Insight Report Eighth Edition. Geneva: World Economic Forum.
101. World Health Organization. (2000). World Health Report 2000. Geneva: WHO Press.
102. World Health Organization. (2010). Antimicrobial Resistance: Revisiting the "Tragedy of the Commons". Bulletin of the World Health Organization. Geneva: WHO Press.
103. World Health Organization. (2014a). Antimicrobial Resistance-Global Report on Surveillance. Geneva: WHO Press.
104. World Health Organization. (2014b). Global Tuberculosis Report. Geneva: WHO Press.
105. World Health Organization. (2015a). Worldwide Country Situation Analysis: Response to Antimicrobial Resistance. Geneva: WHO Press.
106. World Health Organization. (2015b). Antimicrobial Resistance-Draft Global Action Plan, Sixty-eigth World Health Assembly, Provisional Agenda Item 15.1 (A68/20). Geneva: WHO Press.